Fig 2: IFN? secretion by T-LGLL clonotypes drives the activation of the non-leukemic immune cell repertoire.a Expression of selected differentially expressed genes (Padj < 0.05, calculated with Bonferroni corrected two-sided t-test) grouped by their functional pathways between the non-leukemic CD45+ sorted cells from patients with T-LGLL (n = 9) and healthy controls (n = 6). Values are presented as log2 fold-change (log2fc). b Left: Protein level expression (MFI mean fluorescence intensity) of cytotoxic proteins GZMA/B and PRF1 in CD8+CD57- cells in T-LGLL patients (n = 6) and healthy controls (n = 6). Right: The proportion of GZMA/B and PRF1+ CD4+ cells in the flow cytometry cohort. P-values calculated with two-sided Mann-Whitney test. c Upregulated HALLMARK-category pathways (Padj < 0.05, Benjamini-Hochberg corrected Fisher’s one-sided exact test on differentially expressed genes) in non-leukemic cells from T-LGLL (n = 9) in comparison with healthy (n = 6). d Median expression of the IFN? response module score in different immune subsets in patients with T-LGLL (n = 9), healthy controls (n = 6), and patients with other cancers (n = 11). The T-LGLL samples were enriched in the IFN? high cluster (P < 0.05, Fisher’s one-sided exact test). Clustering was performed with Ward’s linkage. e Left: Scaled expression of IFNG in leukemic (red) and non-leukemic (green) populations. P-value was calculated with two-sided Mann-Whitney test. Right: Scaled expression of IFNG in different leukemic (red) and non-leukemic populations (green). Cluster numbers refer to Fig. 2b (leukemic clusters) and Fig. 4a (non-leukemic clusters).